The effects of favipiravir on hematological parameters of covıd-19 patients.
Identifieur interne : 000150 ( Main/Exploration ); précédent : 000149; suivant : 000151The effects of favipiravir on hematological parameters of covıd-19 patients.
Auteurs : Selçuk Yaylaci [Turquie] ; Hamad Dheir [Turquie] ; Didar Enocak [Turquie] ; Ahmed Bilal Genc [Turquie] ; Havva Kocayigit [Turquie] ; Deniz Çekiç [Turquie] ; Ceyhun Var M [Turquie] ; Abdülkadir Ayd N [Turquie] ; Mehmet Koroglu [Turquie] ; O Uz Karabay [Turquie]Source :
- Revista da Associacao Medica Brasileira (1992) [ 1806-9282 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Amides (usage thérapeutique), Betacoronavirus (MeSH), Femelle (MeSH), Humains (MeSH), Hémoglobines (analyse), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Mâle (MeSH), Numération des leucocytes (MeSH), Numération des lymphocytes CD4 (MeSH), Numération des plaquettes (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Pyrazines (usage thérapeutique), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Études rétrospectives (MeSH).
- MESH :
- analyse : Hémoglobines.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Amides, Pyrazines.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Adulte, Adulte d'âge moyen, Betacoronavirus, Femelle, Humains, Mâle, Numération des leucocytes, Numération des lymphocytes CD4, Numération des plaquettes, Pandémies, Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Amides (therapeutic use), Betacoronavirus (MeSH), CD4 Lymphocyte Count (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Female (MeSH), Hemoglobins (analysis), Humans (MeSH), Leukocyte Count (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Platelet Count (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pyrazines (therapeutic use), Retrospective Studies (MeSH).
- MESH :
- chemical , analysis : Hemoglobins.
- chemical , therapeutic use : Amides, Pyrazines.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Aged, 80 and over, Betacoronavirus, CD4 Lymphocyte Count, Female, Humans, Leukocyte Count, Male, Middle Aged, Pandemics, Platelet Count, Retrospective Studies.
Abstract
INTRODUCTION
This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections.
METHODS
Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed. Hematologic parameters were analyzed before and after the treatment.
RESULTS
The mean age of the patients receiving treatment with favipiravir was 63.7±12.3 years. Nasopharyngeal swab positivity was detected in 67.7%. The most common comorbid conditions detected in patients were hypertension in 25 cases (40.3%) and diabetes in 16 cases (25.8%). In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected; the mean RBC was found to have decreased from 4.33 ± 0.58 M/uL to 4.16 ± 0.54 M/uL (p:0.003); the median hemoglobin level was found to have decreased from 12.3 g/dl to 11.9 g/dl (p:0.041); the hematocrit level decreased from 38.1% ± 4.8 to 36.9% ± 4.2 (p:0.026); the median neutrophil count decreased from 4.57 K/uL to 3.85 K/uL (p:0.001); the mean lymphocyte count increased from 1.22 ± 0.53 K/uL to 1.84 ± 1.19 K/uL (p:0.000); and the mean platelet count increased from 244.1 ± 85.1 K/uL to 281.9 ± 103.3 K/uL (p:0.005).
CONCLUSION
We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters.
DOI: 10.1590/1806-9282.66.S2.65
PubMed: 32965359
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effects of favipiravir on hematological parameters of covıd-19 patients.</title><author><name sortKey="Yaylaci, Selcuk" sort="Yaylaci, Selcuk" uniqKey="Yaylaci S" first="Selçuk" last="Yaylaci">Selçuk Yaylaci</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Dheir, Hamad" sort="Dheir, Hamad" uniqKey="Dheir H" first="Hamad" last="Dheir">Hamad Dheir</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey=" Enocak, Didar" sort=" Enocak, Didar" uniqKey=" Enocak D" first="Didar" last=" Enocak">Didar Enocak</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Genc, Ahmed Bilal" sort="Genc, Ahmed Bilal" uniqKey="Genc A" first="Ahmed Bilal" last="Genc">Ahmed Bilal Genc</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Kocayigit, Havva" sort="Kocayigit, Havva" uniqKey="Kocayigit H" first="Havva" last="Kocayigit">Havva Kocayigit</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Education and Research Hospital, Department of Intensive Care, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Education and Research Hospital, Department of Intensive Care, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Cekic, Deniz" sort="Cekic, Deniz" uniqKey="Cekic D" first="Deniz" last="Çekiç">Deniz Çekiç</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Var M, Ceyhun" sort="Var M, Ceyhun" uniqKey="Var M C" first="Ceyhun" last="Var M">Ceyhun Var M</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Ayd N, Abdulkadir" sort="Ayd N, Abdulkadir" uniqKey="Ayd N A" first="Abdülkadir" last="Ayd N">Abdülkadir Ayd N</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Education and Research Hospital, Department of Family Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Education and Research Hospital, Department of Family Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Koroglu, Mehmet" sort="Koroglu, Mehmet" uniqKey="Koroglu M" first="Mehmet" last="Koroglu">Mehmet Koroglu</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine Department Medical Microbiology, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine Department Medical Microbiology, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Karabay, O Uz" sort="Karabay, O Uz" uniqKey="Karabay O" first="O Uz" last="Karabay">O Uz Karabay</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine Department of Infectious Diseases, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine Department of Infectious Diseases, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32965359</idno><idno type="pmid">32965359</idno><idno type="doi">10.1590/1806-9282.66.S2.65</idno><idno type="wicri:Area/Main/Corpus">000126</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000126</idno><idno type="wicri:Area/Main/Curation">000126</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000126</idno><idno type="wicri:Area/Main/Exploration">000126</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The effects of favipiravir on hematological parameters of covıd-19 patients.</title><author><name sortKey="Yaylaci, Selcuk" sort="Yaylaci, Selcuk" uniqKey="Yaylaci S" first="Selçuk" last="Yaylaci">Selçuk Yaylaci</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Dheir, Hamad" sort="Dheir, Hamad" uniqKey="Dheir H" first="Hamad" last="Dheir">Hamad Dheir</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey=" Enocak, Didar" sort=" Enocak, Didar" uniqKey=" Enocak D" first="Didar" last=" Enocak">Didar Enocak</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Genc, Ahmed Bilal" sort="Genc, Ahmed Bilal" uniqKey="Genc A" first="Ahmed Bilal" last="Genc">Ahmed Bilal Genc</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Kocayigit, Havva" sort="Kocayigit, Havva" uniqKey="Kocayigit H" first="Havva" last="Kocayigit">Havva Kocayigit</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Education and Research Hospital, Department of Intensive Care, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Education and Research Hospital, Department of Intensive Care, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Cekic, Deniz" sort="Cekic, Deniz" uniqKey="Cekic D" first="Deniz" last="Çekiç">Deniz Çekiç</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Var M, Ceyhun" sort="Var M, Ceyhun" uniqKey="Var M C" first="Ceyhun" last="Var M">Ceyhun Var M</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Ayd N, Abdulkadir" sort="Ayd N, Abdulkadir" uniqKey="Ayd N A" first="Abdülkadir" last="Ayd N">Abdülkadir Ayd N</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Education and Research Hospital, Department of Family Medicine, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Education and Research Hospital, Department of Family Medicine, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Koroglu, Mehmet" sort="Koroglu, Mehmet" uniqKey="Koroglu M" first="Mehmet" last="Koroglu">Mehmet Koroglu</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine Department Medical Microbiology, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine Department Medical Microbiology, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author><author><name sortKey="Karabay, O Uz" sort="Karabay, O Uz" uniqKey="Karabay O" first="O Uz" last="Karabay">O Uz Karabay</name><affiliation wicri:level="1"><nlm:affiliation>. Sakarya University Faculty of Medicine Department of Infectious Diseases, Sakarya,Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>. Sakarya University Faculty of Medicine Department of Infectious Diseases, Sakarya</wicri:regionArea><wicri:noRegion>Sakarya</wicri:noRegion></affiliation></author></analytic><series><title level="j">Revista da Associacao Medica Brasileira (1992)</title><idno type="eISSN">1806-9282</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Amides (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>CD4 Lymphocyte Count (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Female (MeSH)</term><term>Hemoglobins (analysis)</term><term>Humans (MeSH)</term><term>Leukocyte Count (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Platelet Count (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pyrazines (therapeutic use)</term><term>Retrospective Studies (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Amides (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hémoglobines (analyse)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Mâle (MeSH)</term><term>Numération des leucocytes (MeSH)</term><term>Numération des lymphocytes CD4 (MeSH)</term><term>Numération des plaquettes (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Pyrazines (usage thérapeutique)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Hemoglobins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amides</term><term>Pyrazines</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Hémoglobines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amides</term><term>Pyrazines</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Betacoronavirus</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>Humans</term><term>Leukocyte Count</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Platelet Count</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Betacoronavirus</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Numération des leucocytes</term><term>Numération des lymphocytes CD4</term><term>Numération des plaquettes</term><term>Pandémies</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed. Hematologic parameters were analyzed before and after the treatment.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The mean age of the patients receiving treatment with favipiravir was 63.7±12.3 years. Nasopharyngeal swab positivity was detected in 67.7%. The most common comorbid conditions detected in patients were hypertension in 25 cases (40.3%) and diabetes in 16 cases (25.8%). In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected; the mean RBC was found to have decreased from 4.33 ± 0.58 M/uL to 4.16 ± 0.54 M/uL (p:0.003); the median hemoglobin level was found to have decreased from 12.3 g/dl to 11.9 g/dl (p:0.041); the hematocrit level decreased from 38.1% ± 4.8 to 36.9% ± 4.2 (p:0.026); the median neutrophil count decreased from 4.57 K/uL to 3.85 K/uL (p:0.001); the mean lymphocyte count increased from 1.22 ± 0.53 K/uL to 1.84 ± 1.19 K/uL (p:0.000); and the mean platelet count increased from 244.1 ± 85.1 K/uL to 281.9 ± 103.3 K/uL (p:0.005).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32965359</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1806-9282</ISSN><JournalIssue CitedMedium="Internet"><Volume>66Suppl 2</Volume><Issue>Suppl 2</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Revista da Associacao Medica Brasileira (1992)</Title><ISOAbbreviation>Rev Assoc Med Bras (1992)</ISOAbbreviation></Journal><ArticleTitle>The effects of favipiravir on hematological parameters of covıd-19 patients.</ArticleTitle><Pagination><MedlinePgn>65-70</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0104-42302020001400065</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/1806-9282.66.S2.65</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed. Hematologic parameters were analyzed before and after the treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of the patients receiving treatment with favipiravir was 63.7±12.3 years. Nasopharyngeal swab positivity was detected in 67.7%. The most common comorbid conditions detected in patients were hypertension in 25 cases (40.3%) and diabetes in 16 cases (25.8%). In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected; the mean RBC was found to have decreased from 4.33 ± 0.58 M/uL to 4.16 ± 0.54 M/uL (p:0.003); the median hemoglobin level was found to have decreased from 12.3 g/dl to 11.9 g/dl (p:0.041); the hematocrit level decreased from 38.1% ± 4.8 to 36.9% ± 4.2 (p:0.026); the median neutrophil count decreased from 4.57 K/uL to 3.85 K/uL (p:0.001); the mean lymphocyte count increased from 1.22 ± 0.53 K/uL to 1.84 ± 1.19 K/uL (p:0.000); and the mean platelet count increased from 244.1 ± 85.1 K/uL to 281.9 ± 103.3 K/uL (p:0.005).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yaylaci</LastName><ForeName>Selçuk</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6768-7973</Identifier><AffiliationInfo><Affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dheir</LastName><ForeName>Hamad</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-3569-6269</Identifier><AffiliationInfo><Affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Şenocak</LastName><ForeName>Didar</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-9840-9004</Identifier><AffiliationInfo><Affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genc</LastName><ForeName>Ahmed Bilal</ForeName><Initials>AB</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1607-6355</Identifier><AffiliationInfo><Affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocayigit</LastName><ForeName>Havva</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8719-7031</Identifier><AffiliationInfo><Affiliation>. Sakarya University Education and Research Hospital, Department of Intensive Care, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Çekiç</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7114-9334</Identifier><AffiliationInfo><Affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varım</LastName><ForeName>Ceyhun</ForeName><Initials>C</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8369-0857</Identifier><AffiliationInfo><Affiliation>. Sakarya University Faculty of Medicine, Department of Internal Medicine, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aydın</LastName><ForeName>Abdülkadir</ForeName><Initials>A</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-0663-586X</Identifier><AffiliationInfo><Affiliation>. Sakarya University Education and Research Hospital, Department of Family Medicine, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koroglu</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5918-4479</Identifier><AffiliationInfo><Affiliation>. Sakarya University Faculty of Medicine Department Medical Microbiology, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karabay</LastName><ForeName>Oğuz</ForeName><Initials>O</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1514-1685</Identifier><AffiliationInfo><Affiliation>. Sakarya University Faculty of Medicine Department of Infectious Diseases, Sakarya,Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Assoc Med Bras (1992)</MedlineTA><NlmUniqueID>9308586</NlmUniqueID><ISSNLinking>0104-4230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EW5GL2X7E0</RegistryNumber><NameOfSubstance UI="C462182">favipiravir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010976" MajorTopicYN="N">Platelet Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32965359</ArticleId><ArticleId IdType="pii">S0104-42302020001400065</ArticleId><ArticleId IdType="doi">10.1590/1806-9282.66.S2.65</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Turquie</li></country></list><tree><country name="Turquie"><noRegion><name sortKey="Yaylaci, Selcuk" sort="Yaylaci, Selcuk" uniqKey="Yaylaci S" first="Selçuk" last="Yaylaci">Selçuk Yaylaci</name></noRegion><name sortKey=" Enocak, Didar" sort=" Enocak, Didar" uniqKey=" Enocak D" first="Didar" last=" Enocak">Didar Enocak</name><name sortKey="Ayd N, Abdulkadir" sort="Ayd N, Abdulkadir" uniqKey="Ayd N A" first="Abdülkadir" last="Ayd N">Abdülkadir Ayd N</name><name sortKey="Cekic, Deniz" sort="Cekic, Deniz" uniqKey="Cekic D" first="Deniz" last="Çekiç">Deniz Çekiç</name><name sortKey="Dheir, Hamad" sort="Dheir, Hamad" uniqKey="Dheir H" first="Hamad" last="Dheir">Hamad Dheir</name><name sortKey="Genc, Ahmed Bilal" sort="Genc, Ahmed Bilal" uniqKey="Genc A" first="Ahmed Bilal" last="Genc">Ahmed Bilal Genc</name><name sortKey="Karabay, O Uz" sort="Karabay, O Uz" uniqKey="Karabay O" first="O Uz" last="Karabay">O Uz Karabay</name><name sortKey="Kocayigit, Havva" sort="Kocayigit, Havva" uniqKey="Kocayigit H" first="Havva" last="Kocayigit">Havva Kocayigit</name><name sortKey="Koroglu, Mehmet" sort="Koroglu, Mehmet" uniqKey="Koroglu M" first="Mehmet" last="Koroglu">Mehmet Koroglu</name><name sortKey="Var M, Ceyhun" sort="Var M, Ceyhun" uniqKey="Var M C" first="Ceyhun" last="Var M">Ceyhun Var M</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000150 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000150 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32965359
|texte= The effects of favipiravir on hematological parameters of covıd-19 patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32965359" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |